This study will evaluate the impact that GI complaints have on patient-reported outcomes and to determine if there is improvement in patient-reported outcomes when converted from mycophenolate mofetil (MMF) to Enteric-coated mycophenolate sodium (EC-MPS)
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
200
Novartis Investigative Site
Busan, South Korea
Novartis Investigative Site
Seoul, South Korea
Symptom severity is assessed by the GSRS (GI Symptom Rating Scale); Health-related Quality of Life (HRQL) is assessed by the GIQLI (GI Quality of Life) Index.
Impact of immunosuppressive-induced GI symptoms on patient's perception of symptom severity and HRQL.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.